2024-516773-69-00招募中2 期
Evaluation of the safety and efficacy of Berubicin in the treatment of central nervous system lymphomas- BERUBICIN
Pomeranian Medical University1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2024年11月18日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- To evaluate the safety and tolerability of Berubicin in combination with other cytostatic agents and to determine the recommended Phase 2 dose (RP2D) of Berubicin
研究概览
简要总结
To evaluate the safety and tolerability of Berubicin in combination with other cytostatic agents and to determine the recommended Phase 2 dose (RP2D) of Berubicin
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Written informed consent prior to any study-related procedure, and willing and able to comply with the protocol and aware of the investigational nature of this study.
- •At least 18 years of age.
- •Confirmation of a diagnosis: a. For patients with primary central nervous system lymphoma i. A diagnosis of central nervous system lymphoma confirmed by a pathologist on brain tissue or on the meningeal or cranial nerve lesion b. For patients with non-Hodgkin’s lymphoma i. A diagnosis of non-Hodgkin’s lymphoma confirmed by a pathologist on the lymph node biopsy. ii. Confirmed involvement of the CNS (brain, meninges, cranial nerves, eyes and/or spinal cord) at diagnosis (concomitant to extra-CNS disease) or relapse after conventional chemo(-immuno)therapy iii. Diagnosis of CNS involvement either by biopsy or CSF cytopathologic or cytometric examination. Neuroimaging alone is acceptable when a stereotactic biopsy is formally contraindicated or when the disease has been previously histologically documented in other areas and the CNS localization is concomitant with a diffuse progression of systemic disease.
- •No previous treatment with high-dose methotrexate-based chemotherapy. For patients with non-Hodgkin’s lymphoma up to two courses of R-CHOP are allowed as upfront therapy in patients with advanced disease. The decision is made by the Investigator.
- •No prior investigational therapy within 4 weeks before the first dose of study drug
- •The Eastern Cooperative Oncology Group (ECOG) Performance Status 0-
- •Eligible for chemotherapy based on adequate bone marrow function cardiac, kidney and liver function as defined by the following laboratory guidelines, subject to the Investigator’s discretion: a. Hematopoietic function: platelet count ≥75 x 109/L, hemoglobin ≥8 g/dL, absolute neutrophil count (ANC) ≥1 x 109/L, unless due to organ involvement b. Cardiac function: ejection fraction LVEF ≥45%. c. Renal function: creatinine ≤2 x the upper limit of normal (ULN), unless due to organ involvement. d. Hepatic function: bilirubin ≤3 × ULN (excluding Gilbert's Syndrome, for which bilirubin must be ≤4 × ULN), and/or aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase <3 × ULN, unless due to organ involvement or Gilbert’s Syndrome.
- •Women of childbearing potential must agree to practice a highly effective method of contraception beginning at least 28 days before the start of treatment until at least 3,5 months after the last dose of study drug. Male study patients and their female sexual partners of childbearing potential must agree to practice a highly effective method of contraception starting from the time of informed consent until at least 3,5 months after the last dose of study drug. a. A woman of childbearing potential is defined as a woman who is not permanently sterilized or postmenopausal. Postmenopausal is defined as 12 months with no menses without an alternative medical cause. b. Women of childbearing potential must have a negative serum or urine pregnancy test. c. A highly effective method of birth control is defined as one which results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence, or vasectomized partner. For patients using a hormonal contraceptive method, information regarding all medications being administered to the patient and their potential effect on the contraceptive should be addressed.
排除标准
- •Unable or not willing to comply with the protocol regulations.
- •Patients that are pregnant, lactating, or not using adequate contraception.
- •Contraindications to the use of anthracyclines.
- •Presence of uncontrolled, active viral, bacterial, or fungal infection.
- •Severe heart failure (NYHA III/IV) with EF <45%, severe renal disease (CKD ≥ 4) and / or severe liver disease or cirrhosis (bilirubin > 3 mg/dL or ALT / AST > 3x ULN) not due to organ involvement.
- •History of unstable coronary artery disease CCS>2 or myocardial infarction within the last 6 months.
- •Previous treatment with autologous or allogeneic stem cells/bone marrow transplantation.
- •Presence of human immunodeficiency virus (HIV) infection and of detectable hepatitis C virus RNA (HCV-RNA) and/or hepatitis B virus surface antigen (HBsAg) and/or hepatitis B virus DNA (HBV-DNA).
- •Concurrent malignancies (with exceptions of BCC and cervical cancer in situ). Previous malignancies are accepted if surgically cured or if there was no evidence of disease in the last 2 years at a regular follow-up.
- •Any other serious medical condition which, in the opinion of the Investigator, could impair the ability of the patient to participate in the trial or comply with the study protocol and follow-up schedule.
结局指标
主要结局
To evaluate the safety and tolerability of Berubicin in combination with other cytostatic agents and to determine the recommended Phase 2 dose (RP2D) of Berubicin
To evaluate the safety and tolerability of Berubicin in combination with other cytostatic agents and to determine the recommended Phase 2 dose (RP2D) of Berubicin
次要结局
- To evaluate Progression Free Survival (PFS), defined as the time interval from the date of the first study drug administration to the date of first documentation of progressive disease (PD) or death (whichever occurs first) at 2 years in patients with Primary Central Nervous System Lymphoma and secondary Non-Hodgkin’s Lymphoma with CNS involvement treated with Berubicin-containing chemotherapeutic regimens
- To assess overall response rate (ORR), defined as the proportion of participants who achieved a CR or PR at the end of therapy as assessed by the Investigator according to the most recent "Lugano Response Criteria for NHL" [1] or the "Response Criteria of the International Primary CNS Lymphoma Collaborative Group - IPCG" [2] criteria
- To assess the effect of Berubicin on overall survival (OS) defined as the time interval from the date of the first study drug administration to the date of death at 2 years
- Proportion of patients achieving CR at 12 months
- Proportion of patients achieving PR at 12 months
- To assess the effect of Berubicin on event-free survival (EFS), defined as the length of time from the initiation of study drug administration to disease progression, death, or discontinuation of treatment for any reason (e.g., toxicity, intolerance, disease-related conditions, or failure to respond)
- To evaluate the concentration of complement factors (C3, C4, C5), CRP protein, and circulating miRNA particles in subjects’ plasma and CSF fluid using genomic microarray assessment
- To confirm the pharmacokinetic (PK) profile of Berubicin and its metabolite, berubicinol
研究者
Sławomir Milczarek
Scientific
Pomeranian Medical University
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell LymphomasNCT07278856City of Hope Medical Center20
尚未招募
不适用
A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.Breast CancerNCT07290166Fudan University42
招募中
2 期
Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard TreatmentNCT07275216City of Hope Medical Center23
进行中（未招募）
1/2 期
DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anticancer agents in patients with HER2-positive Metastatic Breast Cancer inclusive of patients with active and stable brain metastases2023-505309-18-00AstraZeneca AB46
尚未招募
1 期
Study of TYK-01054 Capsules in Patients With Advanced Solid TumorsNCT07282873TYK Medicines, Inc219